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Abstract We investigated prevalence of sexually trans-
mitted infections (STI) in a cohort of HIV-1-infected
pregnant women and described factors associated with STI
diagnosis, as a nested study within the European Collabo-
rative Study (ECS). The ECS is a cohort study in which
HIV-infected pregnant women are enrolled and their chil-
dren followed from birth, according to standard clinical and
laboratory protocols. Information on STIs diagnosed dur-
ing pregnancy was collected retrospectively from the
antenatal records of women enrolling between January
1999 and October 2005; other variables were obtained
from the ECS prospective database. A total of 1,050
women were included: 530 in Western Europe and 520 in
Ukraine. Syphilis was the most common bacterial STI (2%
prevalence, 95% CI 1.2–3.0). Prevalence of HPV-related
genital lesions was 8.6% (95%CI 6.9–10.4) and prevalence
of Trichomonas vaginalis was 12.1% (95%CI 10.2–14.2).
Women in Ukraine (AOR 10.7, 95%CI 3.7–30.5), single
women (AOR 3.9, 95%CI 1.2–12.7), sexual partners of
injecting drug users (AOR 3.8, 95%CI 1.4–10.4) and
women with CD4 counts \200 cells/mm3 (AOR 5.4,
95%CI 1.0–28.1) were at increased risk of diagnosis with
Chlamydia trachomatis, syphilis or Trichomonas vaginalis.
African origin (AOR 1.9, 95%CI 1.1–3.3) and CD4 count
\200 cells/mm3 (AOR 3.4, 95%CI 1.5–7.8) were associ-
ated with HSV-2 and/or HPV-related genital lesions.
Antenatal screening should be considered an effective tool
for diagnosis, treatment and prevention of further trans-
mission of STIs. HIV-infected women should receive
adequate screening for STIs during pregnancy together
with appropriate counseling and follow-up for treatment
and prevention.
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Introduction
The number of women living with the human immunodefi-
ciency virus (HIV) has dramatically risen in both Western
and Eastern Europe during the last decade, reflecting both
increased survival associated with highly active antiretrovi-
ral therapy (HAART) and increasing incidence, particularly
in parts of Eastern Europe[1–4]. In the last decade, the
character of the HIV epidemic among women in Europe has
changed substantially. In Western Europe, heterosexual
acquisition has now replaced injecting drug use (IDU) as the
most common mode of acquisition among women, with a
substantial majority of women infected heterosexually
originating from countries with generalized epidemics [1, 5].
In Eastern Europe, there has been a 20-fold increase in HIV
prevalence in less than a decade [2] and a shift in the epi-
demic beyond initial core groups of IDUs, to bridging groups
and into the general population, with the number of HIV
infections reported as heterosexually acquired nearly dou-
bling between 2001 and 2004 in Eastern Europe [1, 5, 6].
This increasing impact of sexual transmission in the
propagation of HIV has spawned a considerable amount of
research focusing on the relationship between sexually
transmitted infections (STIs) and HIV. While both STIs and
HIV share common acquisition risk factors such as high risk
sexual behaviour, they also appear to have an ‘‘epidemio-
logical synergy’’ [7, 8]. First, HIV seems to increase the risk
of acquiring an STI [9] and secondly, STIs appear to increase
the risk of both acquiring and transmitting HIV [10].
Most evidence for this epidemiological synergy is derived
from research in the sexual transmission of HIV and the
potential impact that STIs may have on maternal to child
transmission (MTCT) of HIV has not been clearly quanti-
fied. An important first step in attempting to describe the role
of STIs in MTCT of HIV is to estimate the prevalence of
STIs amongst HIV-infected pregnant women, and to
describe risk factors associated with their acquisition. To
date, the prevalence and risk factors associated with STIs
have been characterized amongst pregnant and non-pregnant
women in the general population [11–15] and in non-preg-
nant HIV-infected women [16, 17], but not comprehensively
amongst HIV-infected pregnant women. We took the
opportunity to investigate the prevalence of STIs and asso-
ciations between STI and socio-demographic characteristics
of women as determined by current antenatal screening
practices in a sub-set of the European Collaborative Study
(ECS), a long-running MTCT cohort study [5, 18].
Methods
The ECS is a prospective cohort study in which HIV-
infected pregnant women are enrolled and followed in
pregnancy, and their children followed from birth, according
to standard clinical and laboratory protocols [18]. The cohort
began in 1985 and includes centres from Western and
Central Europe and, most recently, Ukraine [5]. At each
centre, women identified as HIV-infected during pregnancy,
as well as those women identified as HIV-infected prior to
pregnancy, were invited to participate. Before enrollment,
informed consent was obtained according to local guidelines
and ethics approval was granted in each centre. Maternal
information routinely collected within the study protocol
included socio-demographic characteristics, obstetrical his-
tory and HIV-specific information, but not STI infections.
Women from 15 ECS centres from seven countries were
included in the nested STI study (Western Europe: Spain,
Italy, the United Kingdom, Belgium, Sweden, Germany;
and Ukraine). Information on STIs diagnosed during
pregnancy was collected retrospectively from the antenatal
records of women who delivered between January 1999
and October 2005 in all but the Ukrainian centres. This
period was truncated to between January 2003 and May
2005 for the Ukrainian centres because of the large num-
bers of pregnant women enrolling in these centres, on
average 200–250 women per year.
All centres followed the 1998 and, subsequently, the
2002 Centers for Disease Control guidelines for screening,
diagnosis and treatment of STIs in pregnancy, except for
one centre in Belgium with its own guidelines [19, 20]. All
centres screened for STIs occurred during the first prenatal
visit (12–28 weeks gestational age) and considered all
women to be in the high risk category for STI screening on
the basis of their HIV status, however screening practices
differed slightly among centres.
There was no routine screening of C. trachomatis in one
Western European centre, while all other centres routinely
screened using endocervical sampling. C. trachomatis was
rescreened for in the third trimester by all but two Western
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European centres. N. gonorrhea was not routinely screened
for in two Western European centres, with one additional
Western European centre not rescreening in the third tri-
mester. All centres screened all women for syphilis using
serological testing and all but two Western European
centres rescreened for syphilis in the third trimester. All
centres screened for cervical neoplasia only during the first
trimester by Papanicolaou smear and all but two Western
centres routinely screened all women by clinical exam in
the first trimester for vulvar or vaginal lesions (indicating
HSV-2 or genital warts). Women with abnormal cervical
cytology or diagnosed cervical neoplasia were classified as
having HPV-related genital lesions, as were women with
genital warts. T. vaginalis was diagnosed on a case finding
basis of symptomatic women as per screening guidelines.
Maternal variables included in the analysis were: age at
delivery, region of birth, ethnicity, marital status and mode
of HIV acquisition. Variables considered as proxies for
sexual behaviour risk included: number of previous thera-
peutic pregnancy terminations, previous pregnancies and
reporting a high risk sexual partner (e.g. IDUs). Laboratory
variables included maternal CD4 cell counts and HIV RNA
viral loads at enrollment; in the Ukraine centres, HIV RNA
viral load quantification was not available, and CD4 cell
count available for only a limited number of women due to
lack of laboratory diagnostic capacity. Women with CD4
cell counts of \200 cells/mm3 were classified as severely
immunosuppressed.
Univariable analyses of factors associated with diagnosis
with (1) C. trachomatis and/or syphilis and/or T. vaginalis
and (2) HPV-related genital lesions and/or HSV-2 were
carried out using the Pearson v2test. Crude odds ratios (ORs)
were calculated and variables were selected for testing the fit
of the multivariable model with a significance level of
P \ 0.10 due to the small number of infections. Multivari-
able logistic regression was used to adjust for several factors
simultaneously, to obtain adjusted odds ratios (AOR) and
95% confidence intervals (CI). Given the significant con-
founding of the variables region of birth, centre and ethnicity
due to the homogeneity of the population from some of the
centres, some variables were considered to be a priori risk
factors (i.e. region of birth for viral STIs) based on other
studies and given priority in the multivariable analysis [21].
All analyses were conducted using Intercooled STATA
Version 9.0 (Stata Corporation, Texas, USA).
Results
Study population
Of the 1,050 women, 520 (49.5%) were from centres in
Ukraine and 530 (50.5%) were enrolled in the Western
European centres. Socio-demographic characteristics are
shown in Table 1. In Ukraine, 97% of women were white
and born in Eastern Europe whereas over a third of women
in the Western Europe centres were black Africans. Overall
mean age at time of delivery was 28.3 years (95% CI 27.9–
28.7), with women living in Western Europe significantly
older than those in Ukraine (31.3 vs. 25.9 years; t = 16.2,
P = 0.00). Women in Ukraine were more likely to be
married compared to women in Western Europe (44% vs.
31%; P \ 0.001). Overall, 19% of women reported having
a history of injecting drug use (IDU) (Table 1), with no
significant geographic differences (P = 0.50) and only 27
women reported IDU during their pregnancy. Women in
the Ukraine were much more likely to report being the
sexual partner of an IDU than women in the West (45.8%
vs. 13.8%; P = 0.00).
Overall 45% (n = 473) of women were aware of their
HIV diagnosis when they became pregnant and the
remainder were identified through antenatal testing
(n = 531, 51%) or through rapid testing at delivery
(n = 29, 3%) (for 17 women the test date was not avail-
able). Median maternal CD4 cell count was 409 cells/mm3
(range 7–1,790) and 10.2% (59/579) of women were
classified as severely immunosuppressed (\200 cells/
mm3). Black women were more likely to be severely im-
munosuppressed than white women (17% (29/174) vs. 8%
(24/298), P = 0.002). Median RNA HIV viral load was
2,400 copies/ml (n = 371), with 52% of women having
viral loads over 1,000 copies/ml.
Prevalence of STIs
Table 2 shows the prevalence of individual STIs in centres
in Western Europe and the Ukraine, and for the total
cohort. Overall, 257 women had an antenatal diagnosis
with at least one bacterial or viral STI (24.5%). Of these
women, 18 (1.7%) were diagnosed with two or more
infections. Although for some infections there were similar
prevalences in the Western European compared with the
Ukrainian centres, there was a significantly higher preva-
lence of T. vaginalis (P \ 0.001) and syphilis (P = 0.007)
in Ukraine, with a higher prevalence of HPV-related gen-
ital lesions in Western Europe (P \ 0.001).
Overall, 155 (15%) women were diagnosed with at least
one bacterial STI and 89% (140/158) of these infections
were in women from the Ukraine. Regarding differential
policies for re-screening for C. trachomatis, prevalence in
sites with third trimester re-screening was 0.84% (6/714;
95% CI 0.3–1.8), not significantly different to that in the
two sites with no re-screening (1.45%, 4/275, 95% CI 0.4–
3.9) (Fisher’s exact test, P = 0.48). Although prevalence of
syphilis was higher in centres re-screening for syphilis than
HIV-1 infected pregnant women in Europe 927
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Table 1 Maternal and pregnancy characteristics, by geographic region
Western Europe (N = 530) Ukraine (N = 520) Total (N = 1,050)
N (%) N (%) N (%)
Region of birth
Western Europe 222 (43) – 222 (21)
Eastern Europe 13 (3) 509 (98) 522 (50)
Africa 187 (35) – 189 (18)
Other 11 (2) 2 11 (1)
Unknown 97 (18) 9 (2) 106 (10)
Ethnicity
White 240 (45) 505 (97) 745 (71)
Black 188 (36) – 188 (18)
Other 8 (2) 13 (3) 21 (2)
Unknown 94 (18) 2 96 (9)
Age (years)
15–19 9 (2) 29 (6) 38 (4)
20–24 45 (9) 206 (40) 251 (24)
25–29 105 (20) 165 (32) 270 (26)
30–34 130 (25) 89 (17) 219 (21)
35–39 115 (22) 29 (6) 144 (14)
‡40 26 (5) 1 27 (3)
Unknown 87 (17) 1 88 (9)
Marital status
Single 57 (11) 64 (12) 121 (12)
Married 164 (31) 228 (44) 392 (37)
Cohabiting 107 (20) 222 (43) 329 (31)
Divorced, separated, widowed 36 (7) 2 38 (4)
Unknown 166 (31) 4 170 (16)
Previous pregnancy
Yes (‡1) 403 (76) 304 (42) 707 (67)
No 127 (24) 216 (58) 343 (33)
Previous pregnancy termination
0 249 (47) 311 (60) 560 (53)
1 133 (25) 102 (20) 235 (22)
2 61 (11) 56 (11) 117 (11)
‡3 31 (6) 47 (9) 78 (7)
Unknown 56 (11) 4 (1) 60 (6)
Sexual partner of IDU
Yes 73 (14) 238 (46) 311 (30)
No 426 (80) 272 (52) 698 (67)
Unknown 31 (6) 10 (2) 41 (4)
History of IDU
Yes 97 (18) 107 (21) 204 (19)
No 409 (77) 406 (78) 815 (78)
Unknown 24 (5) 7 (1) 31 (3)
Timing of HIV Diagnosis
Pre-pregnancy 339 (64) 134 (26) 473 (45)
Antenatal Screening 173 (33) 358 (69) 531 (50)
Delivery 7 (1) 22 (4) 29 (3)
Unknown 11 (2) 6 (1) 17 (2)
928 M. Landes et al.
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in those with a single screening, this did not achieve sta-
tistical significance (2.3% [19/841, 95% CI 1.4–3.5] vs.
1.0% [2/209, 95% CI 0.1–3.4]; Fisher’s exact test
P = 0.40). In total, 108 women (10%) were diagnosed with
at least one viral STI.
Factors associated with STI diagnosis
Timing of HIV diagnosis was not univariably associated
with risk of being diagnosed with an STI in pregnancy
(v2 = 0.32, P = 0.57); overall, the prevalence of an STI
was 23.4% for women diagnosed pre-pregnancy and 25.2%
for those diagnosed during pregnancy/at delivery.
Factors univariably associated with antenatal diagnosis
with syphilis, C. trachomatis or T. vaginalis among women
from centres with universal screening for these infections
included birth and/or residence in Ukraine, single or
cohabiting marital status, current IDU and reported previ-
ous or current partner who used injecting drugs and HIV
diagnosis during pregnancy (increased risk) and black
race and age above 30 years (decreased risk) (Table 3). In
the subgroup of women with CD4 cell counts available, the
same risk factors were identified univariably, but race,
marital status and current IDU were no longer associated
with a statistically significant increased risk.
In multivariable logistic regression analysis of 337
women with CD4 cell counts available, women from
Table 1 continued
Western Europe (N = 530) Ukraine (N = 520) Total (N = 1,050)
N (%) N (%) N (%)
CD4 cell count(cells/mm3)
\200 57 (11) 2 59 (6)
200–499 276 (52) 43 (9) 319 (30)
‡ 500 156 (29) 45 (9) 201 (19)
Unknown 41 (8) 430 (83) 471 (45)
HIV RNA load (copies/ml)
\50 65 (12) – 65 (6)
50–1,000 96 (18) – 96 (9)
1001–10,000 98 (19) – 98 (9)
10,001–100,000 95 (18) – 95 (9)
[ 100,000 17 (3) – 17 (2)
Unknown 159 (30) 520 (100) 679 (65)
Antenatal antiretroviral use
Yes 424 (80) 415 (80) 839 (80)
No 96 (18) 105 (20) 201 (19)
Unknown 10 (2) – 10 (1)
Table 2 Prevalence of sexually transmitted infections, by geographic area and for the whole cohort
Western Europe Ukraine Total
N % (95% CI) N % (95% CI) Na % (95% CI)
Bacterial/protozoal STI
Chlamydia trachomatisa 5/445 1.1 (0.3–2.6) 5/520 1.0 (0.3–2.2) 10/965 1.0 (0.5–1.9)
Neisseria gonorrheaa 1/332 0.3 (0.003–0.6) 0 – 1/852 0.1 (0.003–0.6)
Syphilisa 4/530 0.8 (0.2–1.9) 17/520 3.3 (1.9–5.2) 21/1,050 2.0 (1.2–3.0)
Trichomonas vaginalisb 9/530 1.7 (0.8–3.2) 118/520 22.7(19.2–26.5) 127/1,050 12.1 (10.2–14.2)
Viral STI
Herpes simplex virus 2a 4/256 1.6 (0.8–2.7) 8/520 1.5 (0.7–3.0) 12/776 1.5 (0.8–2.7)
Herpes simplex virus 2b 15/161 9.3 (5.3–14.9)
HPV-related genital lesionsa 81/530 15.3 (12.3–18.6) 9/520 1.7(0.8–3.3) 90/1,050 8.6 (6.9–10.4)
a cases over total screened, limited to centres with universal screening
b case-finding among symptomatic women
HIV-1 infected pregnant women in Europe 929
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Ukraine were almost 11 times more likely than other
women to have an antenatal diagnosis of syphilis, C. tra-
chomatis or T. vaginalis, single women had almost a four-
fold increased risk compared with married women and
women with IDU sexual partners had a near four-fold
increased risk (Table 3). Women with severe immuno-
suppression were nearly five and a half times more likely to
have a bacterial STI diagnosed than women with CD4 cell
counts [ 500 cells/mm3.
Univariable analyses identified several factors associ-
ated with an increased likelihood of diagnosis with HSV-2
and/or HPV-related genital lesions in pregnancy, including
being born in Africa, maternal age over 30 years, sepa-
rated, divorced or widowed marital status and severe
immunosuppression (Table 4). Being born in Ukraine and/
or residence in the Ukraine, having an IDU sexual partner
and HIV diagnosis at antenatal screening visit were asso-
ciated with a decreased risk of HSV-2 and/or HPV-related
genital lesions. Similar risks were identified within the
subgroup of women with CD4 cell counts, except being the
sexual partner of an IDU lost statistical significance and
timing of HIV diagnosis was only of borderline signifi-
cance; in this subgroup, women who were severely
immunosuppressed were almost five times more likely to
be diagnosed with HSV-2 and/or HPV than those with CD4
cell counts above 499 cells/mm3. Only women born in
Africa and women who were severely immunosuppressed
remained at a statistically significant increased risk of these
viral STI in multivariable analysis, with the former having
nearly a doubled risk compared with Western European
women and the latter a three-fold increased risk vs.
immunocompetent women (Table 4). Women born in
Ukraine remained much less likely to be diagnosed with
HSV-2 and/or HPV than those born in Western Europe.
Discussion
In this European study, 25% of HIV-infected women were
diagnosed with one or more STIs during their pregnancy,
with 15% diagnosed with at least one bacterial STI and
10% with HSV-2 infection or HPV-related genital lesions.
Marked geographic differences in the prevalence of STIs
existed with women in Ukraine having much higher
prevalence rates of syphilis and T. vaginalis than women in
Western Europe, of whom just over a third were black
African women. The higher prevalence of syphilis in
Ukraine reflects regional estimates reported by the World
Health Organization where the population incidence of
syphilis in the Ukraine was nearly 50–100 times that
reported in the most Western European countries [22].
Likewise, our estimate of T. vaginalis as the most com-
monly diagnosed STI in pregnancy in Ukraine is consistent
with WHO surveillance data [12]. The dramatic rise in
incidence of STIs in Ukraine and other regions in the
former USSR associated with economic transition indicates
an increase in prevalence of risky sexual behaviours [23]
and is likely to have been instrumental in the rapid evo-
lution of the HIV epidemic in Ukraine, where there is now
an estimated HIV prevalence of 1–1.5% [2].
Viral STIs demonstrated the inverse geographical rela-
tionship to bacterial STIs, with prevalence in Western
Europe substantially higher than in Ukraine. Of note, the
prevalence of HSV-2 in Western Europe was double that in
Ukraine, with over 60% of diagnosed HSV-2 infections in
Western Europe occurring in African women. This regional
difference likely reflects the more heterogeneous popula-
tion of the Western European centres, with significant
migration from African countries with higher prevalences
of viral STIs. Given the natural history of viral STIs, that is
their persistence and tendency for episodic reactivation
[24], and the timing of antenatal screening tests, it is likely
that many viral infections diagnosed during pregnancy
represent infections acquired before pregnancy, thus plac-
ing women from highly endemic regions of Africa at
increased risk where, for example, prevalence levels for
HSV-2 in some countries reach 80% [25–27].
The literature suggests that a higher prevalence of bac-
terial and viral STIs can be expected in HIV-infected cohorts
than in non-HIV infected cohorts even after controlling for
sexual behaviour [9, 28, 28, 29]. While our overall STI
prevalence estimates are consistent with those from another
recent study of HIV-infected non-pregnant women in Eur-
ope, the prevalences of chlamydia and gonorrhea were
notably lower [16]. However, a recent study by Chen et al.
of HIV-infected pregnant women in New York found sim-
ilarly low chlamydia and gonorrhea prevalence [30].
Relatively little is known about sexual behaviour in
pregnancy in the general population, and even less in the
HIV-infected pregnant population. This study has similar
limitations, lacking sufficient sexual behaviour data
amongst our cohort. However, pregnancy indicates that
unprotected sex has occurred and several studies in the
general population have suggested that pregnancy is not a
time of decreased sexual risk-taking [31, 32]. In a recent
European survey of reproductive choices and sexual prac-
tices among HIV-infected women, including 121 pregnant
women, 12% abstained from sex during pregnancy and of
those sexually active, 58% were not using barrier contra-
ception [33].
Our finding that single women and those with a history
of having sex with an IDU were significantly more likely to
be diagnosed with a bacterial STI infection is consistent
with the literature, where both variables have been used as
proxies for high risk sexual behaviour in the general pop-
ulation and amongst HIV-infected individuals [11, 34].
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Table 4 Univariable and multivariable analysis of risk factors for HSV-2 and/or HPV-associated genital lesions
Total cohort (n = 1,050) Sub-group with CD4 counts (n = 579) Multivariable analysis
% OR (95%CI) P value % OR (95%CI) P value AOR (95%CI) P value
Region of birth
Western Europe 14.9 1.0 15.5 1.0 1.0
Eastern Europe 3.3 0.2 (0.1–0.4) \0.001 2.9 0.2 (0.05–0.5) \0.003 0.17 (0.05–0.6) 0.007
Africa 25.4 1.9 (1.2–3.2) 0.01 27.3 2.0 (1.2–3.4) 0.005 2.0 (1.2–3.6) 0.01
Other 9.1 0.6 (0.1–4.6) 0.60 9.1 0.5 (0.06–4.4) 0.57 0.8 (0.09–6.7) 0.83
Centre location
Western Europe 17.2 1.0 17.8 1.0
Ukraine 3.3 0.2 (0.1–0.3) \0.001 3.3 0.2 (0.05–0.5) 0.002
Ethnicity
White 6.7 1.0 11.2 1.0
Black 25.0 4.6 (2.0–7.2) \0.001 26.4 2.9 (1.8–4.6) \0.001
Other 9.5 1.5 (0.3–6.5) 0.62 25.0 2.6 (0.5–13.6) 0.24
Age Adjusted for
age with a
continuous variable
Age 0.94 (0.9–1.0) 0.01
15–19 7.9 1.0 (0.3–3.7) 0.9 25.0 2.5 (0.6–11.1) 0.22
20–24 7.6 1.0 11.7 1.0
25–29 9.3 1.2 (0.7–2.3) 0.5 18.1 1.7 (0.7–3.8) 0.22
30–34 16.4 2.4 (1.3–4.3) 0.004 24.4 2.4 (1.1–5.4) 0.03
‡35 9.4 1.3 (0.6–2.5) 0.51 10.2 0.9 (0.4–2.1) 0.73
Marital status
Single 10.7 1.4 (0.7–2.8) 0.33 18.3 1.5 (0.7–3.1) 0.34
Married 7.9 1.0 13.4 1.0
Cohabiting 10.6 1.4 (0.8–2.3) 0.21 19.1 1.5 (0.9–2.8) 0.16
Divorced/widowed/separated 28.9 4.7 (2.2–10.5) \0.001 28.1 2.5 (1.1–6.1) 0.04
Previous pregnancy
0 9.6 1.0 15.0 1.0
‡1 10.6 1.1 (0.7–1.7) 0.62 15.7 1.1 (0.6–1.8) 0.84
Previous termination
0 9.8 1.0 15.5 1.0
1 14.0 1.5 (0.9–2.4) 0.09 20.8 1.4 (0.9–2.4) 0.17
2 7.7 0.8 (0.4–1.6) 0.48 10.9 0.7 (0.3–1.6) 0.31
‡3 6.4 0.6 (0.2–1.6) 0.34 9.5 0.6 (0.2–1.7) 0.31
Sexual partner of injecting drug user
Yes 5.8 0.4 (0.3–0.7) 0.002 16.7 0.7 (0.3–1.3) 0.23
No 12.3 1.0 11.7 1.0
History of injecting drugs
Yes 9.3 0.9 (0.5–1.5) 0.60 13.6 0.8 (0.5–1.5) 0.50
No 10.6 1.0 16.2 1.0
Injected drugs during pregnancy
Yes 7.4 0.7 (0.2–3.0) 0.62 28.6 1.9 (0.4–10.2) 0.44
No 10.4 1.0 17.1 1.0
Timing of diagnosis
Pre-pregnancy 14.8 1.0 17.8 1.0
Antenatal Screening 6.8 0.4 (0.3–0.6) 0.00 12.0 0.6 (0.4–1.0) 0.06 0.5 (0.3–0.9) 0.03
Delivery 3.5 0.2 (0.03–1.5) 0.12 33.3 2.3 (0.2–25.9) 0.5 3.2 (0.2–57.7) 0.43
HIV-1 infected pregnant women in Europe 933
123
Consistent condom use by male IDUs is reportedly low and
condom use is often less common with their primary sexual
partners than with casual sexual partners [35], thus women
with IDU sex partners are at risk from their partners’ risk
behaviors with both sexual and injecting partners.
In our study, women with severe immunosuppression
were substantially more likely to be diagnosed with a STI,
independent of other factors. McClelland et al. found
similarly increased risks and hypothesized that HIV disease
progression may influence susceptibility to bacterial STIs,
duration of infection and/or response to treatment [9]. This
and other studies have shown an increased prevalence of
viral STIs with increasing immunodeficiency [9, 36, 37].
Frequent sub-clinical and clinical reactivations of viral
infections and prolonged duration of infection with
progressive immunodeficiency have been documented in
HIV-infected persons co-infected with viral STIs [38].
Recent studies have indicated the important interactions
between HIV RNA levels and CD4 counts with prevalent
and incident detection of viral STIs, in particular HPV [39].
However, few studies have the statistical power to include
a stratified analysis of combined HIV RNA levels and CD4
counts, including ours.
With regard to HPV infection prevalence, we will have
underestimated the true prevalence in this population, as
we report on the prevalence of clinical manifestations of
HPV infection as identified with a Pap smear or clinical
exam rather than a definitive diagnosis of HPV infection.
The presence of genital lesions/abnormal cervical cytology
has high sensitivity for underlying HPV infection, but low
specificity, as HPV infection will not necessarily lead to
cytological abnormalities. Furthermore, there are issues
regarding the interpretation of Pap smears in the first tri-
mester, due to normal physiological changes at that time.
Although HPV prevalence is known to be higher in
younger women, abnormal cervical cytology or diagnosed
cervical neoplasia are more common in older women,
which explains our finding of an increased risk of HPV-
associated lesions in women aged 30–34 years [40].
Our study has several limitations: first, as this nested
study is within a multi-centre observational study, preva-
lence data may be affected by differential screening
practices. However, for infections such as syphilis which
was universally screened for, we can be confident in our
prevalence estimates. Whilst most studies have shown
association between the risk of STIs and high risk sexual
behaviour, the data available on sexual behaviour in the
ECS consists mostly of distal indicators or proxy measures.
Finally, as the information collected on STI diagnosis was
cross-sectional (i.e. limited to pregnancy), we had no
information on the timing of acquisition of STIs, only that
they were diagnosed in pregnancy.
Our findings demonstrate a substantial prevalence of
coinfection with STIs in pregnant HIV-infected women in
Europe. Antenatal screening should be considered an
effective tool for the diagnosis, treatment and prevention of
further transmission of STIs. The identification and treat-
ment of STIs in this population will not only benefit the
individual woman and her sexual partners, but also her
infant with the protection from adverse outcomes including
congenital infection. It is therefore imperative that HIV-
infected women receive adequate screening for STIs during
the antenatal period and appropriate counseling and follow-
up for treatment and prevention.
Table 4 continued
Total cohort (n = 1,050) Sub-group with CD4 counts (n = 579) Multivariable analysis
% OR (95%CI) P value % OR (95%CI) P value AOR (95%CI) P value
CD4 count (cells/mm3)
\200 40.0 5.8 (2.9–11.6) \0.001 5.2 (2.4–11.1) \0.001
200–499 14.7 1.6 (0.9–2.7) 0.12 1.3 (0.7–2.4) 0.39
‡500 10.0 1.0 1.0
HIV RNA load (copies/ml)
\50 30.8 1.0
50–1,001 11.5 0.3 (0.1–0.7) 0.003
1,001–10,000 8.2 0.2 (0.08–0.5) \0.001
10,001–100,000 27.4 0.8 (0.4–1.7) 0.64
[ 100,000 17.7 0.5 (0.1–1.9) 0.29
unknown 10.6 0.3 (0.1–0.5) \0.001
Antenatal antiretroviral use
Yes 11.2 1.0 16.5 1.0
No 5.5 0.5 (0.2–0.9) 0.02 9.3 0.5 (0.2–1.1) 0.10
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